ABSTRACT
To investigate the efficaciousness of breast-conserving therapy in connection with neoadjuvant chemotherapy on breast cancer. 68 patients, who were confirmed going down with breast cancer and hospitalized from June 2015 and June 2017, were sampled and divided into two groups using the random digit table, i.e. the observation group [n=34] and the control group [n=34]. Patients in the observation group experienced breast-conserving therapy integrated with neoadjuvant chemotherapy, but those in the control group received the radical resection of breast cancer. Patients' condition in surgery, incidence of post-surgery complications as well as patient survivals were compared and coded. In the observation group, surgical duration, intraoperative bleeding amount, length of stay in hospital and incidence rate of post-surgery complications were all lower than the patients with the similar conditions in the control group with evident distinctions in statistics [p<0.05]. In the observation group, survival ratios of one-to-five-year living patients were evidently higher than those in the control group. The distinctions owned evident significance in calculations [p<0.05]. In comparison of the recurrence ratio of disease and the rate of distant metastasis between the observation group [5.88% and 8.82%] and the control group [11.76% and 8.82%], differences had no statistical significance [p>0.05]. Before treatment, compared with the score of life quality in the two groups, no evident distinction in statistical exists [p>0.05], however, after that, the life quality in the observation group evidently outweighs the quality in the control group, which shows the distinctions in statistics [p<0.05]. Breast-conserving therapy in combination with neoadjuvant chemotherapy shows promising clinical value in ameliorating the life quality, decreasing the mortality rate and the incidence of adverse reaction, which is expected to be applied in clinical practices as a kind of safe and effective method